Recombinant Alpha-Gal A Purification via Multi-Step Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing and purifying recombinant human alpha-galactosidase A (rh alpha-Gal A) are limited by contamination with host cell proteins, which can lead to antigen-antibody reactions and the presence of serum-derived contaminants, and do not achieve high enough purity for direct medical use.
Innovation Solution
A method involving culturing rh alpha-Gal A-producing mammalian cells in a serum-free medium followed by a multi-step purification process using anion-exchange, hydrophobic, phosphate-affinity, cation-exchange, dye-affinity, and gel filtration column chromatography to achieve high yield and purity, eliminating host cell proteins and serum contaminants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods (hydrophobic column chromatography, heparin sepharose column chromatography, hydroxylapatite column chromatography, anion-exchange column chromatography, and gel filtration column chromatography) are used, then the purification process can be completed, but the purity is not sufficient for human use due to remaining host cell protein contaminants
Solution Approach 1:
The purification process is divided into multiple sequential chromatography steps, each targeting specific contaminants. The multi-step process includes anion-exchange, hydrophobic interaction, phosphate-affinity, cation-exchange, dye-affinity, and gel filtration chromatography, with each step removing different types of host cell protein contaminants to achieve cumulative purification效果
Solution Approach 2:
Dye-affinity chromatography using Cibacron Blue F3GA serves as an intermediary step that specifically binds to host cell proteins through dye-protein interactions, allowing selective removal of contaminants while preserving the recombinant alpha-galactosidase A activity
2Productivity
If serum-containing medium is used for cell culture, then cell growth is supported, but serum-derived contaminants remain in the purified product
Solution Approach 1:
The serum components are completely removed from the culture system by using defined serum-free medium containing essential nutrients (amino acids, vitamins, inorganic salts, trace elements, carbohydrates, fatty acids, and growth factors). This extraction of harmful serum components eliminates the source of contaminants while maintaining cell viability and productivity through alternative nutrient supplementation
3Manufacturing precision
If multiple purification steps are added to increase purity, then host cell proteins are removed, but the process complexity and cost increase
Solution Approach 1:
Each chromatography step is designed to perform multiple functions: anion-exchange removes basic proteins, hydrophobic interaction removes membrane-associated proteins, phosphate-affinity captures phosphoproteins, cation-exchange removes acidic proteins, dye-affinity specifically binds host cell proteins, and gel filtration performs final polishing and aggregates removal. This multi-functional approach maximizes contaminant removal efficiency at each step
Solution Approach 2:
The purification process exploits differences in multiple protein parameters including charge (anion-exchange, cation-exchange), hydrophobicity (hydrophobic interaction), phosphorylation status (phosphate-affinity), and molecular size (gel filtration). By changing these parameters sequentially, the process achieves high purity while maintaining productivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the production of rh alpha-Gal A with high purity and yield, suitable for direct use as a medical drug, minimizing antigen-antibody reactions and ensuring safety by removing host cell proteins and serum-derived contaminants, while being environmentally and economically favorable.
Implementation Method 1
subjecting the culture supernatant collected in step (b) above to anion-exchange column chromatography to collect the recombinant human alpha-Gal A -active fractions
Implementation Method 2
subjecting the fractions collected in step (c) above to hydrophobic column chromatography to collect recombinant human alpha-Gal A-active fractions
Implementation Method 3
subjecting the fractions collected in step (d) above to a column chromatography employing as solid phase a material having affinity for phosphate group to collect the recombinant human alpha-Gal A-active fractions
Implementation Method 4
subjecting the fractions collected in step (e) above to cation-exchange column chromatography to collect the recombinant human alpha-Gal A -active fractions
Implementation Method 5
subjecting the fractions collected in step (f) above to dye-affinity column chromatography to collect the recombinant human alpha-Gal A -active fractions
Implementation Method 6
subjecting the fractions collected in step (g) above to gel filtration column chromatography to collect the recombinant human alpha-Gal A-active fractions
Data Source
Figure 1
Figure 2-1
Figure 2-2
AI summary
Disclosed is a method for production of recombinant human alpha-galactosidase A (rh alpha-Gal A) in a large scale, with a high purity. The method comprises the steps of (a) culturing rh alpha-Gal A-producing mammalian cells in a serum-free medium, (b) collecting culture supernatant, (c) subjecting the culture supernatant to anion-exchange column chromatography, (d) to hydrophobic column chromatography, (e) to a column chromatography employing as solid phase a material having affinity for phosphate group, (f) to cation-exchange column chromatography, (g) to dye-affinity column chromatography, and (h) to gel filtration column chromatography, in the order.